Search Results - "Yoshizawa, Atsuhiko"

Re‐challenging chemotherapy after pembrolizumab in platinum‐refractory urothelial carcinoma by Uchimoto, Taizo, Fukushima, Tatsuo, Komura, Kazumasa, Fukuokaya, Wataru, Adachi, Takahiro, Hashimoto, Takeshi, Yoshizawa, Atsuhiko, Nakamura, Ko, Yano, Yusuke, Nishimura, Kazuki, Nishio, Kyosuke, Nakamori, Keita, Iwatani, Kosuke, Yamamoto, Shutaro, Urabe, Fumihiko, Mori, Keiichiro, Yanagisawa, Takafumi, Tsuduki, Shunsuke, Takahara, Kiyoshi, Inamoto, Teruo, Miki, Jun, Kimura, Takahiro, Ohno, Yoshio, Shiroki, Ryoichi, Egawa, Shin, Azuma, Haruhito

“…Objectives To assess the real‐world clinical benefit of re‐challenging chemotherapy after pembrolizumab in patients with metastatic urothelial carcinoma (mUC),…”
Get full text

Real‑world survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for nonmetastatic castration‐resistant prostate cancer by Tsujino, Takuya, Tokushige, Satoshi, Komura, Kazumasa, Fukuokaya, Wataru, Adachi, Takahiro, Hirasawa, Yosuke, Hashimoto, Takeshi, Yoshizawa, Atsuhiko, Saruta, Masanobu, Ohno, Takaya, Nakamori, Keita, Maenosono, Ryoichi, Nishimura, Kazuki, Yamazaki, Shogo, Uchimoto, Taizo, Yanagisawa, Takafumi, Mori, Keiichiro, Urabe, Fumihiko, Tsuzuki, Shunsuke, Iwatani, Kosuke, Yamamoto, Shutaro, Takahara, Kiyoshi, Inamoto, Teruo, Kimura, Takahiro, Ohno, Yoshio, Shiroki, Ryoichi, Azuma, Haruhito

“…Background There is little evidence of abiraterone acetate (AA) plus prednisone for patients with non‐metastatic castration‐resistant prostate cancer (nmCRPC)…”
Get full text

Concurrent palliative radiation with pembrolizumab for platinum-refractory urothelial carcinoma is associated with improved overall survival by Nakamori, Keita, Yamazaki, Shogo, Komura, Kazumasa, Fukuokaya, Wataru, Adachi, Takahiro, Hirasawa, Yosuke, Hashimoto, Takeshi, Yoshizawa, Atsuhiko, Ohno, Takaya, Yano, Yusuke, Nishimura, Kazuki, Tokushige, Satoshi, Uchimoto, Taizo, Yamamoto, Shutaro, Iwatani, Kosuke, Urabe, Fumihiko, Mori, Keiichiro, Yanagisawa, Takafumi, Tsuduki, Shunsuke, Takahara, Kiyoshi, Inamoto, Teruo, Miki, Jun, Kimura, Takahiro, Ohno, Yoshio, Shiroki, Ryoichi, Azuma, Haruhito

“…•We investigated the hypothesis that palliative radiation to patients treated with pembrolizumab exerts a favorable effect on survival in 235…”
Get full text

Combined α-methylacyl-CoA racemase inhibition and docetaxel treatment reduce cell proliferation and decrease expression of heat shock protein 27 in androgen receptor-variant-7–positive prostate cancer cells by Yoshizawa, Atsuhiko, Takahara, Kiyoshi, Saruta, Masanobu, Zennami, Kenji, Nukaya, Takuhisa, Fukaya, Kosuke, Ichino, Manabu, Fukami, Naohiko, Niimi, Atsuko, Sasaki, Hitomi, Kusaka, Mamoru, Suzuki, Motoshi, Sumitomo, Makoto, Shiroki, Ryoichi

“…Disease progression in castrate-resistant prostate cancer (PCa) is most commonly driven by the reactivation of androgen receptor (AR) signaling and involves AR…”
Get full text

PD01-03 ALANINE–SERINE–CYSTEINE TRANSPORTER 2 IN GLUTAMINE METABOLISM IS A THERAPEUTIC TARGET FOR RENAL CELL CARCINOMA by Muto, Yoshinari, Sumitomo, Makoto, Saruta, Masanobu, Yoshizawa, Atsuhiko, Takahara, Kiyoshi, Shiroki, Ryoichi

Get full text

Predicting Objective Response of Pembrolizumab in Platinum-Refractory Urothelial Carcinoma Based on Neutrophil-Lymphocyte Ratio Fluctuation and Liver Metastases by Nishio, Kyosuke, Higashio, Takuya, Komura, Kazumasa, Fukuokaya, Wataru, Adachi, Takahiro, Hirasawa, Yosuke, Hashimoto, Takeshi, Yoshizawa, Atsuhiko, Tsuchida, Shuya, Matsuda, Takuya, Tsujino, Takuya, Nishimura, Kazuki, Tokushige, Satoshi, Nakamori, Keita, Uchimoto, Taizo, Yamamoto, Shutaro, Iwatani, Kosuke, Urabe, Fumihiko, Mori, Keiichiro, Yanagisawa, Takafumi, Tsuduki, Shunsuke, Takahara, Kyoshi, Inamoto, Teruo, Miki, Jun, Kimura, Takahiro, Ohno, Yoshio, Shiroki, Ryoichi, Azuma, Haruhito

“…It is well known that patients with objective response to pembrolizumab have a durable duration of response, leading to favorable survival outcomes. We…”
Get more information

Predicting time to castration resistance with androgen-receptor signaling inhibitors in hormone-sensitive prostate cancer: data from ULTRA-Japan Consortium by Uchimoto, Taizo, Iwatsuki, Kengo, Komura, Kazumasa, Fukuokaya, Wataru, Adachi, Takahiro, Hirasawa, Yosuke, Hashimoto, Takeshi, Yoshizawa, Atsuhiko, Saruta, Masanobu, Fujimoto, Saizo, Minami, Takafumi, Yamamoto, Yutaka, Yamazaki, Shogo, Takai, Tomoaki, Sakamoto, Moritoshi, Nakajima, Yuki, Nishimura, Kazuki, Maenosono, Ryoichi, Tsujino, Takuya, Nakamura, Ko, Fukushima, Tatsuo, Nishio, Kyosuke, Yoshikawa, Yuki, Yamamoto, Shutaro, Iwatani, Kosuke, Urabe, Fumihiko, Mori, Keiichiro, Yanagisawa, Takafumi, Tsuduki, Shunsuke, Takahara, Kiyoshi, Inamoto, Teruo, Fujita, Kazutoshi, Kimura, Takahiro, Ohno, Yoshio, Shiroki, Ryoichi, Azuma, Haruhito

“…Androgen-receptor signaling inhibitors (ARSIs) become the new standard of care for metastatic hormone-sensitive prostate cancer (mHSPC). It is unknown whether…”
Get full text

C-Reactive Protein-Albumin Ratio Predicts Objective Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma by Uchimoto, Taizo, Matsuda, Takuya, Komura, Kazumasa, Fukuokaya, Wataru, Adachi, Takahiro, Hirasawa, Yosuke, Hashimoto, Takeshi, Yoshizawa, Atsuhiko, Saruta, Masanobu, Hashimoto, Mamoru, Higashio, Takuya, Tsuchida, Shuya, Nishimura, Kazuki, Tsujino, Takuya, Nakamura, Ko, Fukushima, Tatsuo, Nishio, Kyosuke, Yamamoto, Shutaro, Iwatani, Kosuke, Urabe, Fumihiko, Mori, Keiichiro, Yanagisawa, Takafumi, Tsuduki, Shunsuke, Takahara, Kiyoshi, Inamoto, Teruo, Miki, Jun, Fujita, Kazutoshi, Kimura, Takahiro, Ohno, Yoshio, Shiroki, Ryoichi, Uemura, Hirotsugu, Azuma, Haruhito

“…Background Enfortumab vedotin (EV), an antibody-drug conjugate that targets Nectin-4, is used for patients with metastatic urothelial carcinoma who have…”
Get full text

Prognostic Impact of Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab: A Multicenter Retrospective Study by Nukaya, Takuhisa, Takahara, Kiyoshi, Yoshizawa, Atsuhiko, Saruta, Masanobu, Yano, Yusuke, Ohno, Takaya, Uchimoto, Taizo, Fukuokaya, Wataru, Adachi, Takahiro, Yamazaki, Shogo, Tokushige, Satoshi, Nishimura, Kazuki, Tsujino, Takuya, Nakamori, Keita, Yamamoto, Shutaro, Iwatani, Kosuke, Urabe, Fumihiko, Mori, Keiichiro, Yanagisawa, Takafumi, Tsuduki, Shunsuke, Hirasawa, Yosuke, Hashimoto, Takeshi, Komura, Kazumasa, Inamoto, Teruo, Miki, Jun, Kimura, Takahiro, Ohno, Yoshio, Azuma, Haruhito, Shiroki, Ryoichi

“…Immune checkpoint inhibitors can cause various immune-related adverse events (irAEs). This study aimed to evaluate the association between the incidence of…”
Get full text

Serum C-reactive Protein Level Predicts Overall Survival for Clear Cell and Non-Clear Cell Renal Cell Carcinoma Treated with Ipilimumab plus Nivolumab by Yano, Yusuke, Ohno, Takaya, Komura, Kazumasa, Fukuokaya, Wataru, Uchimoto, Taizo, Adachi, Takahiro, Hirasawa, Yosuke, Hashimoto, Takeshi, Yoshizawa, Atsuhiko, Yamazaki, Shogo, Tokushige, Satoshi, Nishimura, Kazuki, Tsujino, Takuya, Nakamori, Keita, Yamamoto, Shutaro, Iwatani, Kosuke, Urabe, Fumihiko, Mori, Keiichiro, Yanagisawa, Takafumi, Tsuduki, Shunsuke, Takahara, Kiyoshi, Inamoto, Teruo, Miki, Jun, Kimura, Takahiro, Ohno, Yoshio, Shiroki, Ryoichi, Azuma, Haruhito

“…Serum C-reactive protein (CRP) is known to be a biomarker for systemic inflammatory reactions. In the present study, we sought to measure the predictive value…”
Get full text

Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint Inhibitors by Uchimoto, Taizo, Tsuchida, Shuya, Komura, Kazumasa, Fukuokaya, Wataru, Adachi, Takahiro, Hirasawa, Yosuke, Hashimoto, Takeshi, Yoshizawa, Atsuhiko, Saruta, Masanobu, Hashimoto, Mamoru, Higashio, Takuya, Matsuda, Takuya, Nishimura, Kazuki, Tsujino, Takuya, Nakamura, Ko, Fukushima, Tatsuo, Nishio, Kyosuke, Yamamoto, Shutaro, Iwatani, Kosuke, Urabe, Fumihiko, Mori, Keiichiro, Yanagisawa, Takafumi, Tsuduki, Shunsuke, Takahara, Kiyoshi, Inamoto, Teruo, Miki, Jun, Fujita, Kazutoshi, Kimura, Takahiro, Ohno, Yoshio, Shiroki, Ryoichi, Uemura, Hirotsugu, Azuma, Haruhito

“…Background Enfortumab vedotin (EV), an antibody–drug conjugate targeting Nectin-4, has been used for patients with metastatic urothelial carcinoma (mUC) after…”
Get full text

Alanine-Serine-Cysteine Transporter 2 Inhibition Suppresses Prostate Cancer Cell Growth In Vitro by Saruta, Masanobu, Takahara, Kiyoshi, Yoshizawa, Atsuhiko, Niimi, Atsuko, Takeuchi, Toshiyuki, Nukaya, Takuhisa, Takenaka, Masashi, Zennami, Kenji, Ichino, Manabu, Sasaki, Hitomi, Kusaka, Mamoru, Suzuki, Motoshi, Sumitomo, Makoto, Shiroki, Ryoichi

“…Alanine-serine-cysteine transporter 2 (ASCT2) has been associated with increased levels of metabolism in various malignant tumors. However, its biological…”
Get full text

Recurrent Intussusception due to Multiple Intestinal Metastases From Lung Adenocarcinoma by Sato, Harunobu, Ozeki, Shinji, Yoshizawa, Atsuhiko, Okabe, Asako, Kuroda, Makoto, Uyama, Ichiro

“…Metastasis to the small intestine presents occasionally as multiple lesions and is associated with numerous complications. However, metastasis-induced…”
Get full text